GO:0014741 negative regulation of muscle hypertrophy: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0014741 (negative regulation of muscle hypertrophy) describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of muscle hypertrophy.
• Muscle hypertrophy is driven by mechanical load, IGF-1/PI3K/AKT/mTOR signaling, and satellite cell activation, while negative regulators such as myostatin (MSTN) restrain excessive growth.
• Myostatin (MSTN) is a TGF-beta superfamily member that acts as a potent negative regulator of skeletal muscle mass; its loss causes dramatic muscle overgrowth in mice and other species.
• In the heart, pathological hypertrophy is opposed by endogenous negative regulators including MCU, USP28, ALDH2, and clusterin, which modulate calcium handling, antioxidant responses, and remodeling.
• Activin type II receptor (ActRIIA/IIB) blockade relieves negative regulation and promotes maximal skeletal muscle hypertrophy, highlighting therapeutic potential.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of negative regulators in muscle hypertrophy.
Description
Muscle hypertrophy is the enlargement of muscle tissue due to an increase in the size of individual muscle fibers, driven by increased protein synthesis, satellite cell fusion, and mechanical load. While much research focuses on positive drivers of growth, the body also possesses robust negative regulatory mechanisms that prevent excessive or pathological muscle enlargement. GO:0014741, negative regulation of muscle hypertrophy, captures these braking processes that stop, prevent, or reduce the frequency, rate, or extent of muscle hypertrophy. Understanding these negative regulators is critical because their dysregulation contributes to conditions such as muscle wasting, cardiac hypertrophy, and heart failure. In skeletal muscle, myostatin (MSTN) is a classic negative regulator; its genetic deletion leads to widespread muscle hyperplasia and hypertrophy in mice. In the heart, pathological hypertrophy is opposed by factors such as MCU, USP28, ALDH2, and clusterin, which modulate calcium handling, antioxidant responses, and remodeling. This article synthesizes authoritative GO annotations and real PubMed literature to provide a research-grade overview of GO:0014741, its mechanisms, key genes, disease relevance, and experimental approaches.
negative regulation of muscle hypertrophy At A Glance
| GO ID | GO:0014741 |
|---|---|
| GO term | negative regulation of muscle hypertrophy |
| Ontology | biological_process |
| Synonym | none |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of muscle hypertrophy |
| Related positive process | muscle hypertrophy (GO:0014732) |
| Key negative regulators | MSTN, ACVR2A, ACVR2B, USP28, MCU, ALDH2, CLU |
| Disease relevance | Muscle wasting, cardiac hypertrophy, heart failure, cancer cachexia |
What Is GO:0014741?
According to the Gene Ontology, GO:0014741 (negative regulation of muscle hypertrophy) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of muscle hypertrophy. In other words, it encompasses all molecular and cellular events that act as brakes on the enlargement of muscle tissue, whether in skeletal, cardiac, or smooth muscle contexts.
Why Is negative regulation of muscle hypertrophy Important in Cell Biology?
Negative regulation of muscle hypertrophy is essential for maintaining tissue homeostasis and preventing pathological overgrowth. In skeletal muscle, unrestrained hypertrophy can lead to impaired function, metabolic strain, and increased injury risk, while in the heart, pathological hypertrophy is a major risk factor for heart failure and arrhythmias. Understanding the endogenous brakes on muscle growth provides therapeutic targets for muscle-wasting diseases, sarcopenia, and cardiac remodeling. Moreover, manipulating these pathways with CRISPR-based tools enables precise dissection of causal mechanisms and development of next-generation therapeutics.
• Prevents excessive skeletal muscle growth that could impair mobility and metabolism.
• Restrains pathological cardiac hypertrophy, a leading cause of heart failure.
• Myostatin (MSTN) loss-of-function causes dramatic muscle overgrowth, demonstrating its role as a negative regulator.
• Activin type II receptor blockade relieves negative regulation and promotes maximal muscle hypertrophy.
• USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via TRIM21 deubiquitination.
• MCU elevation by CaMKIIδB limits pathological cardiac remodeling.
• ALDH2 mediates beneficial effects of SGLT2 inhibitors on cardiac remodeling.
• Clusterin regulation in the heart after transverse aortic constriction is linked to remodeling.
• Dysregulation of negative regulators contributes to cancer cachexia and muscle atrophy.
• CRISPR screens can identify novel negative regulators of muscle hypertrophy.
What Happens During negative regulation of muscle hypertrophy?
Myostatin Signaling as a Brake on Muscle Growth
In simple terms: Myostatin is a natural substance that tells muscles to stop growing too much.
Myostatin (MSTN), a TGF-beta superfamily member, is a secreted protein that negatively regulates skeletal muscle mass. In mice, genetic deletion of Mstn results in a dramatic increase in muscle mass due to both hyperplasia and hypertrophy, establishing myostatin as a key negative regulator. Myostatin binds to activin type II receptors (ACVR2A/ACVR2B) and activates SMAD2/3 signaling, which suppresses AKT/mTOR-driven protein synthesis and satellite cell activation. Blockade of ActRIIA/IIB with a dual antibody relieves this inhibition and promotes maximal skeletal muscle hypertrophy, further confirming the negative regulatory role.
Intracellular Negative Regulators of Cardiac Hypertrophy
In simple terms: Inside heart cells, certain proteins act as brakes to prevent the heart from becoming too thick.
In the heart, pathological hypertrophy is opposed by multiple intracellular negative regulators. USP28, a deubiquitinating enzyme, negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21; its inhibition reduces hypertrophy. MCU (mitochondrial calcium uniporter) elevation by CaMKIIδB limits pathological cardiac remodeling, acting as a negative regulator of hypertrophy. ALDH2 mediates the effects of SGLT2 inhibitors on improving cardiac remodeling, suggesting a protective negative regulatory role. Clusterin (CLU) regulation in the heart after transverse aortic constriction is associated with remodeling, and its upregulation may reflect a compensatory negative feedback mechanism.
Signaling Crosstalk and Feedback Inhibition
In simple terms: Different signals talk to each other to keep muscle growth in check.
Negative regulation of muscle hypertrophy involves crosstalk between anabolic and catabolic pathways. The IGF-1/PI3K/AKT/mTOR axis promotes hypertrophy, while negative regulators such as myostatin, AMPK, and FOXO transcription factors oppose it. In cardiac hypertrophy, CaMKIIδB, MCU, and USP28 modulate calcium handling, mitochondrial function, and protein degradation to restrain growth. These feedback loops ensure that hypertrophy is transient and adaptive rather than pathological.
Satellite Cell Quiescence and Fusion Restraint
In simple terms: Muscle stem cells are kept asleep until needed, preventing uncontrolled growth.
Satellite cells are muscle stem cells that, when activated, fuse with existing fibers to promote hypertrophy. Negative regulators such as myostatin maintain satellite cell quiescence and limit their activation and fusion. Disruption of this negative regulation leads to enhanced satellite cell activation and muscle growth, as seen in myostatin knockout mice. Thus, negative regulation of muscle hypertrophy includes control over satellite cell dynamics.
Key Genes Involved in GO:0014741 negative regulation of muscle hypertrophy
The following genes and proteins are established negative regulators of muscle hypertrophy, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MSTN | Secreted TGF-beta family ligand that inhibits muscle growth | Knockout causes muscle overgrowth; target for muscle-wasting therapies |
| ACVR2A | Activin type II receptor mediating myostatin signaling | Blockade promotes hypertrophy; CRISPR KO models |
| ACVR2B | Activin type II receptor mediating myostatin signaling | Dual blockade with ACVR2A enhances muscle mass |
| USP28 | Deubiquitinase that negatively regulates antioxidant response | Promotes cardiac hypertrophy via TRIM21; KO reduces hypertrophy |
| MCU | Mitochondrial calcium uniporter | Elevation by CaMKIIδB limits pathological remodeling |
| ALDH2 | Mitochondrial aldehyde dehydrogenase | Mediates SGLT2i effects on cardiac remodeling |
| CLU | Secreted chaperone clusterin | Regulated in heart after TAC; potential negative feedback |
| TRIM21 | E3 ubiquitin ligase | Target of USP28; modulates antioxidant response |
| CAMK2D | CaMKIIδB isoform | Regulates MCU expression and limits remodeling |
| FOXO1 | Transcription factor | Promotes atrophy and opposes hypertrophy |
| FOXO3 | Transcription factor | Promotes atrophy and opposes hypertrophy |
| AMPK | Energy sensor kinase | Inhibits mTOR and opposes hypertrophy |
| SMAD2 | Transcription factor downstream of myostatin | Mediates negative regulation of muscle growth |
| SMAD3 | Transcription factor downstream of myostatin | Mediates negative regulation of muscle growth |
| MYOG | Myogenic regulatory factor | Involved in differentiation; context-dependent |
| MEF2C | Transcription factor | Modulates hypertrophy gene programs |
| NFATC1 | Calcineurin-responsive transcription factor | Drives pathological hypertrophy; opposed by negative regulators |
How Is negative regulation of muscle hypertrophy Regulated?
Negative regulation of muscle hypertrophy is itself tightly regulated at multiple levels. Myostatin expression is controlled by mechanical load, glucocorticoids, and inflammatory cytokines, and its signaling through ActRIIA/IIB is modulated by follistatin and other binding proteins. In the heart, USP28 activity is regulated by its own ubiquitination and interaction with TRIM21, while MCU expression is controlled by CaMKIIδB. ALDH2 activity is influenced by SGLT2 inhibitors and oxidative stress. Clusterin (CLU) is regulated after transverse aortic constriction, potentially as a compensatory response. These layers of regulation ensure that muscle hypertrophy is appropriately restrained under physiological conditions.
negative regulation of muscle hypertrophy and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MSTN | Muscle wasting, sarcopenia, cachexia | Mstn knockout mouse; AAV-mediated overexpression |
| ACVR2A/ACVR2B | Muscle atrophy, dystrophy | Dual antibody treatment; conditional KO mice |
| USP28 | Cardiac hypertrophy, heart failure | Cardiomyocyte-specific KO; TAC model |
| MCU | Pathological cardiac remodeling | MCU transgenic overexpression; CaMKIIδB KO |
| ALDH2 | Cardiac remodeling, diabetic cardiomyopathy | ALDH2 KO; SGLT2i treatment |
Muscle Wasting and Sarcopenia
Loss of negative regulation of muscle hypertrophy can be beneficial in muscle-wasting conditions. Myostatin inhibition or ActRIIA/IIB blockade promotes muscle growth and is being explored for sarcopenia, cachexia, and muscular dystrophies. Conversely, excessive negative regulation contributes to muscle atrophy. Understanding these mechanisms is key to developing therapies that selectively modulate the brakes on muscle growth.
Cardiac Hypertrophy and Heart Failure
Pathological cardiac hypertrophy is a major precursor to heart failure. Endogenous negative regulators such as USP28, MCU, ALDH2, and clusterin oppose hypertrophic remodeling. Dysregulation of these factors can tip the balance toward pathological growth. Targeting these negative regulators, for example with SGLT2 inhibitors that modulate ALDH2, represents a therapeutic strategy.
Cancer Cachexia
Cancer cachexia involves severe muscle wasting driven by inflammatory cytokines and myostatin. Negative regulation of muscle hypertrophy is overwhelmed in cachexia, and restoring anabolic signaling or inhibiting myostatin can help preserve muscle mass. Research into negative regulators may identify new targets for cachexia intervention.
From negative regulation of muscle hypertrophy-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate skeletal muscle hypertrophy? | CRISPR knockout in C2C12 myotubes or mouse satellite cells |
| Does a point mutation in gene X alter its negative regulatory function? | CRISPR point-mutation knock-in in mouse zygotes or cell lines |
| Does overexpression of gene X suppress hypertrophy? | AAV-mediated overexpression in mouse muscle |
| Does a tagged version of gene X localize correctly and interact with partners? | CRISPR knock-in of FLAG/HA tag |
| Which genes are essential for negative regulation of cardiac hypertrophy? | Genome-wide CRISPR library screening in cardiomyocytes |
| Does modulation of gene X affect cardiac remodeling in vivo? | Transverse aortic constriction (TAC) in conditional KO mice |
How to Study the negative regulation of muscle hypertrophy Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Loss-of-function effects on hypertrophy | Identify novel negative regulators |
| RNA-seq | Transcriptional changes | Profile gene expression after gene manipulation |
| Proteomics | Protein abundance and modifications | Validate targets and pathways |
| Histology/immunofluorescence | Fiber size, myotube diameter | Quantify hypertrophy |
| Echocardiography | Cardiac function and wall thickness | Assess cardiac hypertrophy in vivo |
| Grip strength test | Skeletal muscle function | Evaluate muscle performance |
| Western blot | Protein expression and signaling | Confirm knockout or overexpression |
| Luciferase reporter | Transcriptional activity | Measure SMAD or NFAT activity |
CRISPR Screening for Negative Regulators
Genome-wide CRISPR knockout or activation screens in muscle cells or cardiomyocytes can identify novel negative regulators of hypertrophy. Libraries targeting all genes can be introduced, followed by hypertrophic stimuli and sequencing to identify enriched or depleted sgRNAs.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal changes in gene expression and protein abundance upon manipulation of candidate negative regulators. For example, USP28 knockout alters antioxidant gene expression in the heart, and MCU elevation changes calcium-handling transcripts.
Imaging and Histology
Muscle fiber cross-sectional area, myotube diameter, and cardiac wall thickness are measured by histology and immunofluorescence. These methods directly assess hypertrophy and the impact of negative regulators.
Functional Assays
Grip strength, treadmill running, and echocardiography assess muscle function and cardiac performance in vivo. These are critical for validating whether negative regulators affect physiological outcomes.
How CRISPR Can Be Used to Study GO:0014741 negative regulation of muscle hypertrophy
Knockout
CRISPR knockout of negative regulators such as MSTN or USP28 can be achieved in cell lines or animal models. For example, Mstn knockout mice display dramatic muscle hypertrophy, and Usp28 knockout reduces cardiac hypertrophy. Knockout models are essential to establish causality.
Point Mutation
Point mutations can be introduced to dissect specific domains or phosphorylation sites in negative regulators. For instance, mutating the catalytic cysteine of USP28 or the calcium-binding site of MCU can reveal structure-function relationships.
Knock-in
Knock-in of tags (e.g., FLAG, HA) or reporter genes allows visualization and interaction studies of negative regulators. Tagged MCU or USP28 can be used for co-immunoprecipitation and imaging.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression can elevate levels of negative regulators to test whether they suppress hypertrophy. For example, overexpression of MCU limits pathological remodeling, and overexpression of ALDH2 mimics SGLT2i effects.
How EDITGENE Supports negative regulation of muscle hypertrophy Research
Researchers studying negative regulation of muscle hypertrophy-related genes often need to determine whether a candidate gene is causally involved in restraining muscle growth. This requires precise genetic manipulation, which can be achieved through CRISPR-based knockout, point mutation, knock-in, or overexpression models. EDITGENE provides end-to-end services to generate such models and to screen for novel regulators.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of muscle hypertrophy research.
Frequently Asked Questions About negative regulation of muscle hypertrophy
What is GO:0014741?
GO:0014741 is the Gene Ontology term for negative regulation of muscle hypertrophy, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of muscle hypertrophy.
What genes are involved in negative regulation of muscle hypertrophy?
Key genes include MSTN, ACVR2A, ACVR2B, USP28, MCU, ALDH2, and CLU, among others.
How does myostatin negatively regulate muscle hypertrophy?
Myostatin (MSTN) is a TGF-beta family ligand that binds ActRIIA/IIB receptors, activating SMAD2/3 signaling to suppress protein synthesis and satellite cell activation, thereby limiting muscle growth.
What is the role of USP28 in cardiac hypertrophy?
USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21; its inhibition reduces hypertrophy.
How does MCU limit pathological cardiac remodeling?
Elevated MCU expression by CaMKIIδB limits pathological cardiac remodeling, acting as a negative regulator of hypertrophy.
Can CRISPR be used to study negative regulation of muscle hypertrophy?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect causal roles of negative regulators in muscle hypertrophy.
What diseases are linked to dysregulated negative regulation of muscle hypertrophy?
Muscle wasting, sarcopenia, cancer cachexia, cardiac hypertrophy, and heart failure are linked to altered negative regulation.
What experimental models are used to study negative regulation of muscle hypertrophy?
Common models include Mstn knockout mice, ActRIIA/IIB blockade, cardiomyocyte-specific KO, and transverse aortic constriction.
How does ALDH2 affect cardiac remodeling?
ALDH2 mediates the effects of SGLT2 inhibitors on improving cardiac remodeling, suggesting a protective negative regulatory role.
What is the role of clusterin in cardiac hypertrophy?
Clusterin (CLU) regulation in the heart after transverse aortic constriction is associated with remodeling and may act as a negative feedback mechanism.
Conclusion
GO:0014741 (negative regulation of muscle hypertrophy) encompasses critical biological brakes that prevent excessive muscle growth. Key negative regulators such as myostatin, USP28, MCU, ALDH2, and clusterin have been identified through rigorous studies. Understanding these mechanisms offers therapeutic opportunities for muscle-wasting diseases and cardiac hypertrophy. CRISPR-based models are indispensable for dissecting causality and developing targeted interventions.
References
- 1. Schiaffino S et al.. 2021. Molecular Mechanisms of Skeletal Muscle Hypertrophy.. J Neuromuscul Dis 8(2):169-183 PMID: 33216041
- 2. Nakamura M et al.. 2018. Mechanisms of physiological and pathological cardiac hypertrophy.. Nat Rev Cardiol 15(7):387-407 PMID: 29674714
- 3. Morvan F et al.. 2017. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.. Proc Natl Acad Sci U S A 114(47):12448-12453 PMID: 29109273
- 4. McPherron AC et al.. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.. Nature 387(6628):83-90 PMID: 9139826
- 5. Han J et al.. 2024. Cardiomyocyte-derived USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21.. Theranostics 14(16):6236-6248 PMID: 39431010
- 6. Wang P et al.. 2022. Elevated MCU Expression by CaMKIIδB Limits Pathological Cardiac Remodeling.. Circulation 145(14):1067-1083 PMID: 35167328
- 7. Liu H et al.. 2024. ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling.. Cardiovasc Diabetol 23(1):380 PMID: 39462342
- 8. Turkieh A et al.. 2024. Regulation of Clusterin in the Heart and Plasma of Mice After Transverse Aortic Constriction.. J Cell Mol Med 28(23):e70290 PMID: 39671261
